Mucosta (Rebamipide) API Manufacturers & Suppliers

Rebamipide (CAS Number 90098-04-7) is an organic compound classified within the group of hippuric acids, characterized by a benzoyl group linked to the N-terminal of glycine. It has been investigated primarily for applications in the treatment of stomach ulceration, keratoconjunctivitis sicca (dry eye syndrome), and various gastric mucosal pathologies including gastric adenoma and early-stage gastric cancer.

Clinically, rebamipide is employed as an anti-ulcer agent and gastrointestinal protective compound, with usage contexts including acid-related disorders and peptic ulcer disease. It is approved and used in multiple regions for mucosal protection and healing, although precise global indications and regulatory status may vary.

The mechanism of action of rebamipide is not fully characterized in all sources, but it is understood to exert mucosal protective effects largely through antioxidative properties and enhancement of the gastric mucosal defense system. These include scavenging of free radicals and reactive oxygen species, modulation of inflammatory responses, promotion of mucin secretion, and facilitation of epithelial restitution. As a quinoline derivative, it may contribute to stabilization of the gastric mucosa and support tissue repair processes.

Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) for rebamipide have been described in limited studies. The compound demonstrates moderate oral bioavailability with hepatic metabolism and renal excretion pathways contributing to elimination. Detailed human pharmacokinetic data, including half-life and plasma protein binding specifics, are not comprehensively published.

Safety and toxicity considerations for rebamipide indicate a generally favorable profile, with adverse effects reported infrequently and typically mild. Nonetheless, clinical use requires attention to potential hypersensitivity reactions and monitoring in populations with compromised hepatic or renal function. Comprehensive toxicological assessments supporting regulatory approval underline its suitability for long-term therapy in indicated conditions.

In sourcing rebamipide API, adherence to stringent quality control standards including purity, residual solvents, and impurity profiles is essential. Suppliers should provide documentation demonstrating compliance with current Good Manufacturing Practices (cGMP) and international pharmacopeial specifications where applicable to ensure batch-to-batch consistency for pharmaceutical formulation development.